R & D

Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Opdivo (nivolumab) plus Yervoy (ipilimumab) for Treatment of Mismatch Repair Deficient or Microsatellite Instability–High Metastatic Colorectal Cancer After Prior Chemotherapy

 This material is intended to notify the press release issued on May 21 (local time) by Bristol Myers Squibb, our license partner for Opdivo.
 Please click for the original press release.